ROCKET PHARMACEUTICALS INC
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Stock Option Valuation
The weighted average assumptions that the Company used in a Black-Scholes pricing model to determine the fair value of stock options granted to employees, non-employees and directors were as follows:
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Risk-free interest rate | 4.35% | 5.16% |
| Expected term (in years) | 5.42 | 5.88 |
| Expected volatility | 71.29% | 73.62% |
| Expected dividend yield | 0.00% | 0.00% |
| Exercise price | $10.73 | $29.46 |
| Fair value of common stock | $10.73 | $29.46 |
The following table summarizes stock option activity for thethree months ended March 31, 2025:
| Weighted · Weighted | |||||
|---|---|---|---|---|---|
| Average · Average · Aggregate | |||||
| Number of · Exercise · Contractual · Intrinsic | |||||
| Shares · Price · Term (Years) · Value | |||||
| Outstanding as of December 31, 2024 | 16,044,686 | $16.19 | 4.67 | $63,295 | |
| Granted | 1,414,793 | 10.73 | 9.39 | ||
| Exercised | - | - | - | ||
| Cancelled or forfeited | (258,945) | 21.68 | |||
| Outstanding as of March 31, 2025 | 17,200,534 | $15.66 | 4.71 | $30,666 | |
| Options vested and exercisable as of March 31, 2025 | 13,872,270 | $15.03 | 3.69 | $30,666 | |
| Options unvested as of March 31, 2025 | 3,328,264 | $18.27 | 8.95 | $ | - |
The weighted average grant-date fair value per share of stock options granted during the three months ended March 31, 2025, and 2024 was$6.05 and$19.92, respectively.
The total fair value of options vested during the three months ended March 31, 2025 and 2024 was$10.7 million and$11.5 million, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.